M42 has made its move in Central Asia. The company opened its first Diaverum renal clinic in Bishkek, Kyrgyzstan, showing that the region is now a key focus for advanced, AI-powered healthcare. This step comes as Diaverum marks ten years in Kazakhstan, where it has become the largest private dialysis provider, running over 55 clinics and employing more than 1,000 people.
Diaverum’s public clinic directory confirms its active presence in Kazakhstan, with haemodialysis centers in cities such as Astana, Karaganda, Aksai, and Shakhtinsk.
At launch, the Bishkek clinic will run 15 dialysis stations across three shifts, Monday through Saturday. There are plans to expand to 20 stations as more patients come in. The opening event brought together Amantur Ryskulov, General Manager for Diaverum Southeast Asia and Central Asia; Ziyad Kabli, Chief Operations Officer for M42 Middle East and Asia; and senior officials from the Kyrgyz Ministry of Health, the National Investment agency, the UAE Embassy, and the Honorary Consul of Sweden. Their attendance shows both government support and international interest in M42’s plans for the region.
Kyrgyzstan’s healthcare sector has seen recent reforms, including expanded medicine-supply initiatives and new pharmaceutical logistics projects in Bishkek, which have created a more supportive environment for investments in specialized medical services such as renal care.
Dimitris Moulavasilis, Group CEO of M42, describes the expansion as part of a bigger plan: “At M42, we are building a global health intelligence platform that brings together clinical expertise, technology, data and genomics to address complex health challenges. Our growth in Central Asia demonstrates how our model can support different healthcare priorities from specialized renal care in Kazakhstan and Kyrgyzstan to advancing prevention-first care in Uzbekistan. Through strong local partnerships, we aim to contribute to more connected, sustainable and future-ready healthcare systems across the region that serve people with their healthcare needs.”
In Kazakhstan, Diaverum’s ten-year record stands out. The company started with nine clinics and now runs a nationwide network serving thousands. The Kyrgyzstan launch builds on this, using a decade of experience and local partnerships to make a difference in a neighboring country.
M42’s approach in Central Asia is targeted, not random. Ziyad Kabli, Chief Operating Officer for Middle East & Asia, is clear: “Central Asia is an important growth region for M42 and our approach is grounded in long-term collaboration aligned with local healthcare priorities. Kazakhstan demonstrates what can be achieved through sustained commitment, while our entry into Kyrgyzstan expands access to high-quality renal care. Alongside our partnership in Uzbekistan, these developments demonstrate M42's commitment to more integrated, preventive and data-enabled healthcare across the region.”
With the Bishkek clinic now open, M42 is betting that its mix of AI, genomics, and clinical standards will fill a major gap in Kyrgyzstan’s kidney care and set a new bar for healthcare in the region. The company’s results in Kazakhstan and its growing work in Uzbekistan show this is not a one-off. It is a planned effort to change what is possible for healthcare systems across Central Asia. If M42 delivers on its promise of connected, sustainable, and future-ready care, patients in the region could finally get the level of service they have long needed.
The Diaverum clinic directory lists multiple haemodialysis centers in Kazakhstan, backing up the company’s reputation as a leading provider in the region.
